TargetBeta
HCRTR2
hypocretin receptor 2 · also OX2R, OXR2, ORXR2 · Hypocretin receptors
4 programs in company-led studies act on HCRTR2, from 4 companies: 3 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| daridorexantrule | Idorsia Pharmaceuticals | phase 4 | 341 running | HCRTR1 | ChEMBL |
| HS-10506 | Hansoh Pharmaceutical Group | phase 3 | 66 running | – | the company's pipeline |
| seltorexantrule | Johnson & Johnson | phase 3 | 332 running | – | ChEMBL |
| cleminorexton | Eli Lilly | phase 3 | 11 running | – | a judged reading |
Also acted on by the same programs
Conditions their studies are in
- Sleep Initiation and Maintenance Disorders, 3 programs
- Renal Insufficiency, 2 programs
- Sleep Apnea, Obstructive, 2 programs
- Alzheimer Disease, 1 program
- Depressive Disorder, Major, 1 program
- Lymphoma, Follicular, 1 program
- Narcolepsy, 1 program
- Pulmonary Disease, Chronic Obstructive, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 30, 2026seltorexant · Johnson & Johnson · phase 3 · NCT06559306
- Sep 30, 2027cleminorexton · Eli Lilly · phase 3 · NCT07598708
- Nov 22, 2027daridorexant · Idorsia Pharmaceuticals · phase 4 · NCT07843329
- Jun 1, 2028HS-10506 · Hansoh Pharmaceutical Group · phase 3 · NCT07844967
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.